Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 64 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Schizophrenia Clear all

Conditions: Schizophrenia
Interventions: Lurasidone HCl; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 21
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 18 more

Conditions: Acute Abstinence From Cigarettes vs E-cigarettes (ENDS)
Interventions: Acute (24-hour) abstinence, Ad libitum smoking/vaping; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 21 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Schizophrenia
Interventions: SB-773812, Olanzapine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Cerritos, California • Garden Grove, California + 15 more

Conditions: Schizophrenia
Interventions: LTX-001 once daily, Placebo, LTX-001 twice daily; Drug
Lead sponsor: Leal Therapeutics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Alamitos, California • DeLand, Florida + 6 more

Conditions: Schizophrenia
Interventions: OPC-34712, Placebo, Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 16
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 12 more

Conditions: Schizophrenia
Interventions: PF-02545920, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 10
States / cities: Glendale, California • Lemon Grove, California • Paramount, California + 4 more

Conditions: Schizophrenia
Interventions: PF-00217830, Placebo, Aripiprazole; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Garden Grove, California • Torrance, California • Washington D.C., District of Columbia + 5 more

Conditions: Schizophrenia
Interventions: LB-102; Drug
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 25
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 20 more

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 15
States / cities: Costa Mesa, California • Long Beach, California • Paramount, California + 12 more

Conditions: Agitation
Interventions: Asenapine, Placebo; Drug
Lead sponsor: Unity Health Toronto; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Schizophrenia
Interventions: PEAR-004, Sham; Device
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Garden Grove, California • Oakland, California • Torrance, California + 3 more

Conditions: Acute Schizophrenia, Schizoaffective Disorder
Interventions: RP5063, placebo, aripiprazole; Drug
Lead sponsor: Reviva Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 25
States / cities: Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more

Conditions: Schizophrenia
Interventions: Risperidone ISM 75 mg, Risperidone ISM 100 mg; Drug
Lead sponsor: Rovi Pharmaceuticals Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more

Conditions: Schizophrenia
Interventions: SEP-363856 50mg, SEP-363856 75mg, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 18
States / cities: Little Rock, Arkansas • Anaheim, California • Bellflower, California + 13 more

Conditions: Schizophrenia
Interventions: Iloperidone, Ziprasidone, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 33
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 28 more

Conditions: Schizophrenia
Interventions: RGH-188; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Psychosis; Acute
Interventions: risperidone, aripiprazole; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
Interventions: BXCL501 Sublingual Film; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 5
States / cities: Chino, California • Oceanside, California • Orange, California + 2 more

Conditions: Healthy
Interventions: Delta-9-THC, N-acetylcysteine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Dexmedetomidine Hydrochloride, Placebos; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: Emraclidine 15 mg, Emraclidine 30 mg, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 19
States / cities: Bentonville, Arkansas • Bellflower, California • La Habra, California + 15 more

Conditions: Patients With Schizophrenia and Acute Agitation
Interventions: Inhaled loxapine 5 mg, Inhaled loxapine 10 mg, Inhaled placebo; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Glycine administration; Dietary Supplement
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Belmont, Massachusetts

Search by objective public record fields.

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Vaping and Smoking Project in People With Schizophrenia

SB-773812 Administered In Adults With Schizophrenia

A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia

Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Safety and Efficacy of Cariprazine in Schizophrenia

Treating Acutely Agitated Patients With Asenapine Sublingual Tablets

Study of Efficacy of PEAR-004 in Schizophrenia

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

N-acetylcysteine Effects on Tetrahydrocannabinol

BXCL501 for Agitation in Schizophrenia

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Staccato Loxapine in Agitated Patients With Schizophrenia

Acute Glycine Pharmacodynamic Study